Publications by authors named "Niloufar Shad"
Neurosurg Rev
August 2024
Article Synopsis
- * The combination treatment leads to modest improvements in overall survival (OS) rates, with 2-year OS at 39% for those receiving bevacizumab versus 20% for standard therapy alone.
- * Despite potential benefits, the treatment is associated with a 62% incidence of adverse events, including significant complications like fatigue and CNS hemorrhage, highlighting the need for careful patient
